ongoing

LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in ChinaLakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China

LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China

December 12, 2024 19:57 ET | Source: LakeShore Biopharma Co., Ltd BEIJING, Dec. 12, 2024 (GLOBE NEWSWIRE) -- LakeShore Biopharma…

3 months ago
BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGYBC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

NICOSIA, Cyprus, Dec. 5, 2024 /PRNewswire/ -- BC.GAME, a premier cryptocurrency i-Gaming platform, announced its decision to withdraw its license specifically…

3 months ago
BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGYBC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

NICOSIA, Cyprus, Dec. 5, 2024 /PRNewswire/ -- BC.GAME, a premier cryptocurrency i-Gaming platform, announced its decision to withdraw its license specifically…

3 months ago
BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGYBC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

NICOSIA, Cyprus, Dec. 5, 2024 /PRNewswire/ -- BC.GAME, a premier cryptocurrency i-Gaming platform, announced its decision to withdraw its license specifically…

3 months ago
Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin LymphomaGalapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Galapagos Announces Encouraging New Results from Ongoing Phase 1/2 Study of CD19 CAR T-Cell Therapy, GLPG5101, in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma

Data from the ongoing Phase 1/2 ATALANTA-1 study in a heavily pretreated R/R NHL patient population demonstrate high antitumor activity…

3 months ago
BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGYBC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

NICOSIA, Cyprus, Dec. 5, 2024 /PRNewswire/ -- BC.GAME, a premier cryptocurrency i-Gaming platform, announced its decision to withdraw its license specifically…

3 months ago
BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGYBC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

NICOSIA, Cyprus, Dec. 5, 2024 /PRNewswire/ -- BC.GAME, a premier cryptocurrency i-Gaming platform, announced its decision to withdraw its license specifically…

3 months ago
BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGYBC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

NICOSIA, Cyprus, Dec. 5, 2024 /PRNewswire/ -- BC.GAME, a premier cryptocurrency i-Gaming platform, announced its decision to withdraw its license specifically…

3 months ago
BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGYBC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

BC.GAME CONTINUES ONGOING EFFORTS IN STRENGTHENING ITS GLOBAL COMPLIANCE STRATEGY

NICOSIA, Cyprus, Dec. 5, 2024 /PRNewswire/ -- BC.GAME, a premier cryptocurrency i-Gaming platform, announced its decision to withdraw its license specifically…

3 months ago
Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced CancerPasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

Pasithea Therapeutics Announces Positive Safety Review Committee (SRC) Recommendation from its ongoing Phase 1 Clinical Trial of PAS-004 in Advanced Cancer

-- SRC recommended that the trial escalate to the next dose level of 15mg capsule -- -- No dose-limiting toxicities…

4 months ago
Show more Posts